STOCK TITAN

CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
CymaBay Therapeutics, Inc. will host a conference call and live webcast on November 7, 2023, to discuss financial results for Q3 2023 and provide a business update.
Positive
  • None.
Negative
  • None.

NEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that it will host a conference call and live audio webcast on Tuesday, November 7, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2023 and to provide a business update.

Conference Call Details
To access the live conference call, please dial 1-877-407-0784 from the U.S. and Canada, or 1-201-689-8560 internationally, Conference ID #13740701. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.

About CymaBay

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), Priority Medicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class investigational treatment for people with PBC. Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit www.cymabay.com and follow us on X (formerly Twitter) and Linkedin.

Public Relations Contact:

Theresa Dolge
Evoke Kyne
(609) 915-2156
Theresa.Dolge@evokegroup.com

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com

 


CymaBay Therapeutics will host a conference call and live webcast on November 7, 2023.

The conference call and webcast will cover the financial results for the third quarter ended September 30, 2023, and provide a business update.

To access the live conference call, dial 1-877-407-0784 from the U.S. and Canada, or 1-201-689-8560 internationally, Conference ID #13740701.

You can access the live and subsequently archived webcast of the conference call in the Investors section of the company's website at http://ir.cymabay.com/events.
Cymabay Therapeutics Inc

NASDAQ:CBAY

CBAY Rankings

CBAY Latest News

CBAY Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Newark

About CBAY

cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.